2. Academic Validation
  3. Identification of Small Molecules that Modulate Mutant p53 Condensation

Identification of Small Molecules that Modulate Mutant p53 Condensation

  • iScience. 2020 Sep 1;23(9):101517. doi: 10.1016/j.isci.2020.101517.
Clara Lemos 1,  Luise Schulze 1,  Joerg Weiske 1,  Hanna Meyer 1,  Nico Braeuer 1,  Naomi Barak 1,  Uwe Eberspächer 1,  Nicolas Werbeck 1,  Carlo Stresemann 1,  Martin Lange 1,  Ralf Lesche 1,  Nina Zablowsky 1,  Katrin Juenemann 1,  Atanas Kamburov 1,  Laura Martina Luh 1,  Thomas Markus Leissing 1,  Jeremie Mortier 1,  Michael Steckel 1,  Holger Steuber 1,  Knut Eis 1,  Ashley Eheim 1,  Patrick Steigemann 1
Affiliations

Affiliation

  • 1 Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany.
PMID: 32927263 DOI: 10.1016/j.isci.2020.101517
Abstract

Structural mutants of p53 induce global p53 protein destabilization and misfolding, followed by p53 protein aggregation. First evidence indicates that p53 can be part of protein condensates and that p53 aggregation potentially transitions through a condensate-like state. We show condensate-like states of fluorescently labeled structural mutant p53 in the nucleus of living Cancer cells. We furthermore identified small molecule compounds that interact with the p53 protein and lead to dissolution of p53 structural mutant condensates. The same compounds lead to condensation of a fluorescently tagged p53 DNA-binding mutant, indicating that the identified compounds differentially alter p53 condensation behavior depending on the type of p53 mutation. In contrast to p53 aggregation inhibitors, these compounds are active on p53 condensates and do not lead to mutant p53 reactivation. Taken together our study provides evidence for structural mutant p53 condensation in living cells and tools to modulate this process.

Keywords

Biochemistry Methods; Medical Biochemistry; Structural Biology.

Figures
Products